| scholarly article | Q13442814 |
| P50 | author | Ron Waksman | Q7364511 |
| Jolanta M Siller-Matula | Q37837348 | ||
| Rossella Marcucci | Q42167382 | ||
| Deepak L. Bhatt | Q47264894 | ||
| Richard C Becker | Q57243679 | ||
| Jean-Luc Reny | Q57623465 | ||
| Dominick Angiolillo | Q72837721 | ||
| Paul A Gurbel | Q89230591 | ||
| Dimitrios Alexopoulos | Q89503368 | ||
| Laurent Bonello | Q89646090 | ||
| Gregg W Stone | Q90754539 | ||
| Young Hoon Jeong | Q90917250 | ||
| Ajay J Kirtane | Q93141120 | ||
| Dietmar Trenk | Q95307719 | ||
| Udaya S Tantry | Q98565539 | ||
| Daniel Aradi | Q114304350 | ||
| Jurrien ten Berg | Q114304352 | ||
| Dirk Sibbing | Q114304354 | ||
| Tobias Geisler | Q124254157 | ||
| P2093 | author name string | Elisabeth Mahla | |
| Nick Curzen | |||
| Matthew J. Price | |||
| Sunil V. Rao | |||
| P2860 | cites work | Universal definition of myocardial infarction: Kristian Thygesen, Joseph S. Alpert and Harvey D. White on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction | Q22242900 |
| Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity | Q28196405 | ||
| High platelet reactivity on clopidogrel therapy correlates with increased coronary atherosclerosis and calcification: a volumetric intravascular ultrasound study | Q30450312 | ||
| The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score. | Q33303244 | ||
| Early but not late stent thrombosis is influenced by residual platelet aggregation in patients undergoing coronary interventions | Q33509256 | ||
| Impact of high-responsiveness to dual antiplatelet therapy on bleeding complications in patients receiving drug-eluting stents | Q33533006 | ||
| Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. | Q34020220 | ||
| Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data | Q34060015 | ||
| Adenosine diphosphate–induced platelet-fibrin clot strength: A new thrombelastographic indicator of long-term poststenting ischemic events | Q34111144 | ||
| 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventi | Q34231154 | ||
| Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: systematic review and meta-analysis | Q34306772 | ||
| Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease | Q34633709 | ||
| Recovery of platelet function after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-treated patients with stable coronary disease: the recovery trial | Q34639256 | ||
| Clopidogrel efficacy and cigarette smoking status. | Q34640383 | ||
| Clinical end points in coronary stent trials: a case for standardized definitions | Q36807166 | ||
| Platelet function monitoring in patients with coronary artery disease | Q36990868 | ||
| Bleeding, blood transfusion, and increased mortality after percutaneous coronary intervention: implications for contemporary practice | Q37499351 | ||
| Minimizing the risks of anticoagulants and platelet inhibitors | Q37741667 | ||
| Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. | Q37786695 | ||
| Implications of variability in definition and reporting of major bleeding in randomized trials of oral P2Y12 inhibitors for acute coronary syndromes | Q37882216 | ||
| Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium | Q37889006 | ||
| Assessment of oral antithrombotic therapy by platelet function testing | Q37902507 | ||
| Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance | Q38373039 | ||
| Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation | Q38375573 | ||
| Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction | Q38460956 | ||
| Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy | Q38461756 | ||
| Antiplatelet drug response status does not predict recurrent ischemic events in stable cardiovascular patients: results of the Antiplatelet Drug Resistances and Ischemic Events study. | Q38471154 | ||
| Platelet function measurement-based strategy to reduce bleeding and waiting time in clopidogrel-treated patients undergoing coronary artery bypass graft surgery: the timing based on platelet function strategy to reduce clopidogrel-associated bleedin | Q38475034 | ||
| High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. | Q38484239 | ||
| Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial | Q38485635 | ||
| Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial | Q38493350 | ||
| Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study | Q41968141 | ||
| Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial | Q42164176 | ||
| Clopidogrel responsiveness regardless of the discontinuation date predicts increased blood loss and transfusion requirement after off-pump coronary artery bypass graft surgery | Q42787226 | ||
| Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogr | Q42857052 | ||
| Clinical predictors of dual aspirin and clopidogrel poor responsiveness in stable cardiovascular patients from the ADRIE study | Q42879719 | ||
| Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy | Q42910350 | ||
| Relationship between platelet reactivity inhibition and non-CABG related major bleeding in patients undergoing percutaneous coronary intervention | Q43174983 | ||
| Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement | Q43234546 | ||
| Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment? | Q43279859 | ||
| Dynamics of platelet functional recovery following a clopidogrel loading dose in healthy volunteers | Q43767957 | ||
| Residual platelet reactivity, bleedings, and adherence to treatment in patients having coronary stent implantation treated with prasugrel | Q44305048 | ||
| Clopidogrel and bleeding in patients undergoing elective coronary artery bypass grafting | Q45049123 | ||
| Prasugrel in clinical practice. | Q45928309 | ||
| Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. | Q45947797 | ||
| Onset and offset of platelet inhibition after high-dose clopidogrel loading and standard daily therapy measured by a point-of-care assay in healthy volunteers. | Q45960413 | ||
| Differential prognostic impact of high on-treatment platelet reactivity among patients with acute coronary syndromes versus stable coronary artery disease undergoing percutaneous coronary intervention. | Q45974851 | ||
| Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study. | Q46000153 | ||
| Different prognostic significance of high on-treatment platelet reactivity as assessed by the VerifyNow P2Y12 assay after coronary stenting in patients with and without acute myocardial infarction | Q46055685 | ||
| A therapeutic window for platelet reactivity for patients undergoing elective percutaneous coronary intervention: results of the ARMYDA-PROVE (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity for Outcome | Q46062168 | ||
| Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis | Q46187200 | ||
| Impact of "nuisance" bleeding on clopidogrel compliance in patients undergoing intracoronary drug-eluting stent implantation. | Q46209759 | ||
| Comparison of four tests to assess inhibition of platelet function by clopidogrel in stable coronary artery disease patients | Q46338658 | ||
| Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study | Q46665436 | ||
| Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point | Q46750174 | ||
| Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease | Q46869184 | ||
| Multiple electrode whole-blood aggregometry and bleeding in cardiac surgery patients receiving thienopyridines | Q48303367 | ||
| ??? | Q22242895 | ||
| Association between bleeding events and in-hospital mortality after percutaneous coronary intervention. | Q50491796 | ||
| Tailoring clopidogrel dose according to multiple electrode aggregometry decreases the rate of ischemic complications after percutaneous coronary intervention. | Q50791517 | ||
| The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study. | Q51058215 | ||
| 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiol | Q55056448 | ||
| Personalized antiplatelet treatment after percutaneous coronary intervention: The MADONNA study | Q58071003 | ||
| The balance between pro- and anti-inflammatory cytokines is associated with platelet aggregability in acute coronary syndrome patients | Q59714808 | ||
| Platelet function testing and prediction of procedural bleeding risk | Q61668958 | ||
| Comparison of Prasugrel and Ticagrelor Loading Doses in ST-Segment Elevation Myocardial Infarction Patients | Q63342280 | ||
| Hyperreactive platelets and complications of coronary artery disease | Q69033424 | ||
| Usefulness of platelet response to clopidogrel by point-of-care testing to predict bleeding outcomes in patients undergoing percutaneous coronary intervention (from the Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Bleed | Q83266017 | ||
| An initial experiment with personalized antiplatelet therapy: the GRAVITAS trial | Q83620035 | ||
| Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents?: platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents | Q83630796 | ||
| Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents?: the role of platelet reactivity and genotype testing in the prevention of atherothrombotic cardiovascular events remains unproven | Q83630798 | ||
| A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reac | Q83944505 | ||
| Hypercoagulability, platelet function, inflammation and coronary artery disease acuity: results of the Thrombotic RIsk Progression (TRIP) study | Q84023565 | ||
| Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study | Q84567862 | ||
| Relationship between post-treatment platelet reactivity and ischemic and bleeding events at 1-year follow-up in patients receiving prasugrel | Q84729330 | ||
| Association between inflammatory biomarkers and platelet aggregation in patients under chronic clopidogrel treatment | Q85025557 | ||
| 2012 update to the Society of Thoracic Surgeons guideline on use of antiplatelet drugs in patients having cardiac and noncardiac operations | Q85273430 | ||
| Bedside monitoring to adjust antiplatelet therapy for coronary stenting | Q85345517 | ||
| Evolving pattern of on-prasugrel and on-ticagrelor platelet reactivity over time in ST elevation myocardial infarction patients | Q86190276 | ||
| P433 | issue | 24 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 2261-73 | |
| P577 | publication date | 2013-12-17 | |
| P1433 | published in | Journal of the American College of Cardiology | Q2984355 |
| P1476 | title | Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding | |
| P478 | volume | 62 |
| Q37561275 | "Real-World" Comparison of Prasugrel With Ticagrelor in Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention in the United States |
| Q51747299 | A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Study of the Effects of Tongxinluo Capsules in Acute Coronary Syndrome Patients with High On-Treatment Platelet Reactivity. |
| Q47570792 | A Prospective, Randomized, Open-Label, Blinded, Endpoint Study Exploring Platelet Response to Half-Dose Prasugrel and Ticagrelor in Patients with the Acute Coronary Syndrome: HOPE-TAILOR Study |
| Q35126038 | A comparative pharmacodynamic study of ticagrelor versus clopidogrel and ticagrelor in patients undergoing primary percutaneous coronary intervention: the CAPITAL RELOAD study |
| Q38396256 | A head-to-head pharmacodynamic comparison of prasugrel vs. ticagrelor after switching from clopidogrel in patients with coronary artery disease: results of a prospective randomized study |
| Q36081188 | A pharmacodynamic study of the optimal P2Y12 inhibitor regimen for East Asian patients with acute coronary syndrome |
| Q50991937 | A prospective randomized evaluation of a pharmacogenomic approach to antiplatelet therapy among patients with ST-elevation myocardial infarction: the RAPID STEMI study. |
| Q64284613 | A randomised, investigator-initiated, clinical trial of the effects of fentanyl on P2Y12-receptor inhibition in patients with ST-elevation myocardial infarction who are pre-treated with crushed ticagrelor: rationale and design of the Opioids aNd crus |
| Q35764145 | A study on the impact of CYP2C19 genotype and platelet reactivity assay on patients undergoing PCI |
| Q42700913 | Abciximab as a bridging strategy to overcome morphine-prasugrel interaction in STEMI patients |
| Q48013353 | Accumetrics-based clopidogrel dosing in endovascular neurosurgery |
| Q35803138 | Acetylsalicylic acid desensitization in patients with coronary artery disease: A comprehensive overview of currently available protocols |
| Q38958862 | Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors |
| Q60923308 | Anti-platelet drugs and their necessary interaction with endothelial mediators and platelet cyclic nucleotides for therapeutic efficacy |
| Q38349536 | Antiplatelet Therapy Considerations in Ischemic Cardiogenic Shock: Implications of Metabolic Bioactivation |
| Q48507719 | Antiplatelet Therapy in ACS Patients: Comparing Appropriate P2Y12 Inhibition by Clopidogrel to the Use of New P2Y12 Inhibitors |
| Q51026024 | Antiplatelet drugs and platelet reactivity: is it time to halt clinical research on tailored strategies? |
| Q52903388 | Antiplatelet effects of clopidogrel and aspirin after interventional patent foramen ovale/ atrium septum defect closure. |
| Q88241732 | Antiplatelet strategies in elderly people: still a long way to go |
| Q38796046 | Antiplatelet therapy - a summary for the general physicians. |
| Q49666836 | Antithrombotic efficacy of bivalirudin compared to unfractionated heparin during percutaneous coronary intervention for acute coronary syndrome. |
| Q39147735 | Antithrombotic therapy for patients with STEMI undergoing primary PCI. |
| Q45028902 | Antithrombotic therapy in medically managed patients with non-ST-segment elevation acute coronary syndromes |
| Q92051447 | Association between High Platelet Reactivity Following Dual Antiplatelet Therapy and Ischemic Events in Japanese Patients with Coronary Artery Disease Undergoing Stent Implantation |
| Q39159683 | Association between platelet reactivity and circulating platelet-derived microvesicles in patients with acute coronary syndrome |
| Q55258177 | Association of serum levels of lipoprotein A-I and lipoprotein A-I/A-II with high on-treatment platelet reactivity in patients with ST-segment elevation myocardial infarction. |
| Q91816153 | Bioresorbable Vascular Scaffolds-Dead End or Still a Rough Diamond? |
| Q53224199 | Calcium-Channel Blockers Attenuate the Antiplatelet Effect of Clopidogrel. |
| Q36813106 | Cell-Penetrating Pepducin Therapy Targeting PAR1 in Subjects With Coronary Artery Disease |
| Q91817259 | Circulating MicroRNA Profiling in Non-ST Elevated Coronary Artery Syndrome Highlights Genomic Associations with Serial Platelet Reactivity Measurements |
| Q38380465 | Clinical evidence for oral antiplatelet therapy in acute coronary syndromes |
| Q52593402 | Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention. |
| Q47112558 | Clinical outcomes in patients treated for coronary in-stent restenosis with drug-eluting balloons: Impact of high platelet reactivity. |
| Q93175682 | Clopidogrel Pharmacogenetics |
| Q38640902 | Clopidogrel Response Variability: Review of the Literature and Practical Considerations |
| Q40717885 | Coadministration of ticagrelor and ritonavir: Toward prospective dose adjustment to maintain an optimal platelet inhibition using the PBPK approach |
| Q46253334 | Comparative Long-Term Effect of Three Anti-P2Y12 Drugs after Percutaneous Angioplasty: An Observational Study Based on Electronic Drug Adherence Monitoring. |
| Q59799852 | Compared efficacy of clopidogrel and ticagrelor in treating acute coronary syndrome: a meta-analysis |
| Q64088444 | Comparison of 1-year clinical outcomes between prasugrel and ticagrelor versus clopidogrel in type 2 diabetes patients with acute myocardial infarction underwent successful percutaneous coronary intervention |
| Q35658513 | Comparison of Aggregometry with Flow Cytometry for the Assessment of Agonists´-Induced Platelet Reactivity in Patients on Dual Antiplatelet Therapy |
| Q53257151 | Comparison of pharmacodynamics between low dose ticagrelor and clopidogrel after loading and maintenance doses in healthy Korean subjects. |
| Q87488294 | Comparison of platelet inhibition by prasugrel versus ticagrelor over time in patients with acute myocardial infarction |
| Q36570244 | Comparison of the influence of ticagrelor and clopidogrel on inflammatory biomarkers and vascular endothelial function for patients with ST-segment elevation myocardial infarction receiving emergency percutaneous coronary intervention: study protoco |
| Q57211755 | Comparison of the pharmacodynamic effects of ranolazine versus amlodipine on platelet reactivity in stable patients with coronary artery disease treated with dual antiplatelet therapy : The ROMAN (RanOlazine vs. aMlodipine on platelet reactivity in s |
| Q47258097 | Contemporary antiplatelet therapy in acute coronary syndromes: are there differences in outcomes and discontinuation between clopidogrel and ticagrelor? |
| Q38197732 | Contemporary antiplatelet therapy in patients undergoing percutaneous coronary intervention |
| Q36003227 | Coronary Artery-Bypass-Graft Surgery Increases the Plasma Concentration of Exosomes Carrying a Cargo of Cardiac MicroRNAs: An Example of Exosome Trafficking Out of the Human Heart with Potential for Cardiac Biomarker Discovery |
| Q36419684 | Correlation between the CYP2C19 phenotype status and the results of three different platelet function tests in cardiovascular disease patients receiving antiplatelet therapy: an emphasis on newly introduced platelet function analyzer-200 P2Y test |
| Q34309863 | Creatine kinase inhibits ADP-induced platelet aggregation. |
| Q58804822 | Creatine kinase, energy reserve, and hypertension: from bench to bedside |
| Q38404995 | Crushed Versus Integral Tablets of Ticagrelor in ST-Segment Elevation Myocardial Infarction Patients: A Randomized Pharmacokinetic/Pharmacodynamic Study. |
| Q38571123 | Current Phase II drugs under investigation for the treatment of limb ischemia |
| Q35544048 | Current antiplatelet treatment strategy in patients with diabetes mellitus |
| Q52812029 | Dabigatran enhances platelet reactivity and platelet thrombin receptor expression in patients with atrial fibrillation. |
| Q57143053 | De-Escalation of P2Y12 Receptor Inhibitor Therapy after Acute Coronary Syndromes in Patients Undergoing Percutaneous Coronary Intervention |
| Q61804282 | De-escalation of anti-platelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a narrative review |
| Q47419470 | Decreased platelet inhibition by P2Y12 receptor blockers in anaemia |
| Q93024451 | Design of the randomized, placebo-controlled evolocumab for early reduction of LDL-cholesterol levels in patients with acute coronary syndromes (EVOPACS) trial |
| Q49058595 | Determinants of agreement between proposed therapeutic windows of platelet function tests in vulnerable patients |
| Q47834734 | Determinants of high on-treatment platelet reactivity and agreement between VerifyNow and Multiplate assays |
| Q64118507 | Determinants of high platelet reactivity in patients with acute coronary syndromes treated with ticagrelor |
| Q40670841 | Diabetes mellitus and carotid artery plaques exhibiting high-intensity signals on MR angiography are related to increased platelet reactivity after carotid artery stenting. |
| Q35883494 | Differences in Whole Blood Platelet Aggregation at Baseline and in Response to Aspirin and Aspirin Plus Clopidogrel in Patients With Versus Without Chronic Kidney Disease |
| Q50658902 | Direct factor IXa inhibition with the RNA-aptamer pegnivacogin reduces platelet reactivity in vitro and residual platelet aggregation in patients with acute coronary syndromes. |
| Q41620557 | Disaggregation Following Agonist-Induced Platelet Activation in Patients on Dual Antiplatelet Therapy. |
| Q48026575 | Discordance Between VASP Phosphorylation and Platelet Aggregation in Defining High On-Clopidogrel Platelet Reactivity After ST-Segment Elevation Myocardial Infarction. |
| Q58070771 | Distribution of clinical events across platelet aggregation values in all-comers treated with prasugrel and ticagrelor |
| Q40542171 | Does "smoker's paradox" exist in clopidogrel-treated Turkish patients with acute coronary syndrome |
| Q36104404 | Drug-Free Platelets Can Act as Seeds for Aggregate Formation During Antiplatelet Therapy. |
| Q39129014 | Dual antiplatelet therapy and non-cardiac surgery: evolving issues and anesthetic implications |
| Q50268523 | Dual antiplatelet therapy guided by platelet function testing |
| Q51067690 | Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial. |
| Q39660267 | Dynamic platelet adhesion in patients with an acute coronary syndrome: The effect of antiplatelet therapy |
| Q39055767 | East Asian perspective on the interaction between proton pump inhibitors and clopidogrel. |
| Q93011947 | Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART-CHOICE Randomized Clinical Trial |
| Q46638114 | Effect of long-term adherence to clopidogrel on the VASP-PRI after elective coronary stent implantation: a randomized controlled study. |
| Q39962890 | Effect of preanalytical time-delay on platelet function as measured by multiplate, PFA-100 and VerifyNow |
| Q64948922 | Effect of thrombelastography on timing of coronary artery bypass grafting. |
| Q51070139 | Effect of ticagrelor with clopidogrel on high on-treatment platelet reactivity in acute stroke or transient ischemic attack (PRINCE) trial: Rationale and design. |
| Q48204482 | Effects of genetic variants on platelet reactivity and one-year clinical outcomes after percutaneous coronary intervention: A prospective multicentre registry study |
| Q47792745 | Effects of statin therapy on platelet reactivity after percutaneous coronary revascularization in patients with acute coronary syndrome. |
| Q60310000 | Effects of switching ticagrelor to clopidogrel on cardiovascular outcomes in patients with acute coronary syndrome |
| Q38243854 | Efficacy of clopidogrel treatment and platelet responsiveness in peripheral arterial procedures. |
| Q87985046 | Eicosanoids in platelets and the effect of their modulation by aspirin in the cardiovascular system (and beyond) |
| Q47664216 | Electric impedance platelet aggregometry in cardiac surgery patients: A comparative study of two technologies. |
| Q98161485 | Ethnic Differences in Oral Antithrombotic Therapy |
| Q35208684 | Evaluation of clinical risk factors to predict high on-treatment platelet reactivity and outcome in patients with stable coronary artery disease (PREDICT-STABLE). |
| Q41250240 | Evaluation of the F2R IVS-14A/T PAR1 polymorphism with subsequent cardiovascular events and bleeding in patients who have undergone percutaneous coronary intervention |
| Q38243032 | Expert consensus document: World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI. |
| Q37417319 | Expression and function of purinergic receptors in platelets from apheresis-derived platelet concentrates |
| Q47161058 | Factors related to on-treatment platelet aggregation assessed by multiple electrode aggregometry in percutaneous coronary intervention patients on clopidogrel and aspirin. |
| Q38799118 | First report of the point-of-care TEG: A technical validation study of the TEG-6S system |
| Q89452333 | Flavin monooxygenase 3, the host hepatic enzyme in the metaorganismal trimethylamine N-oxide-generating pathway, modulates platelet responsiveness and thrombosis risk |
| Q38216499 | Front-loading with clopidogrel plus aspirin followed by dual antiplatelet therapy in the prevention of early stroke recurrence |
| Q48689443 | Gender Differences in Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy |
| Q50868428 | Genetic and platelet function testing of antiplatelet therapy for percutaneous coronary intervention: the ARCTIC-GENE study. |
| Q38489014 | Genetically Determined Platelet Reactivity and Related Clinical Implications. |
| Q52589473 | Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points-Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC). |
| Q96025075 | Genome-wide association study of platelet reactivity and cardiovascular response in patients treated with clopidogrel: a study by the International Clopidogrel Pharmacogenomics Consortium (ICPC) |
| Q33837665 | Genomewide Association Study Identifies Novel Genetic Loci That Modify Antiplatelet Effects and Pharmacokinetics of Clopidogrel |
| Q38380508 | Genotyping-guided approach versus the conventional approach in selection of oral P2Y12 receptor blockers in Chinese patients suffering from acute coronary syndrome |
| Q39460818 | Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial |
| Q35955435 | Gut Microbial Metabolite TMAO Enhances Platelet Hyperreactivity and Thrombosis Risk |
| Q40372167 | HIV infection, ACS, PCI and high platelet reactivity: ingredients for a perfect thrombotic storm |
| Q37291972 | Head to Head Comparison of Two Point-of-care Platelet Function Tests Used for Assessment of On-clopidogrel Platelet Reactivity in Chinese Acute Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention |
| Q55175923 | High On-Treatment Platelet Reactivity Associated With Prasugrel. |
| Q89878602 | High Platelet Reactivity after Transition from Cangrelor to Ticagrelor in Hypothermic Cardiac Arrest Survivors with ST-Segment Elevation Myocardial Infarction |
| Q35758891 | High Platelet Reactivity in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: Randomised Controlled Trial Comparing Prasugrel and Clopidogrel |
| Q38844348 | High platelet reactivity after P2Y12-inhibition in patients with atrial fibrillation and coronary stenting |
| Q97588555 | Higher neutrophil-to-lymphocyte ratio (NLR) increases the risk of suboptimal platelet inhibition and major cardiovascular ischemic events among ACS patients receiving dual antiplatelet therapy with ticagrelor |
| Q90177046 | Highlights from the 2019 International Aspirin Foundation Scientific Conference, Rome, 28 June 2019: benefits and risks of antithrombotic therapy for cardiovascular disease prevention |
| Q53837582 | How to test the effect of aspirin and clopidogrel in patients on dual antiplatelet therapy? |
| Q48737764 | Immature platelet fraction and high-on treatment platelet reactivity with ticagrelor in patients with acute coronary syndromes |
| Q64911959 | Impact of Antithrombotic Regimen and Platelet Inhibition Extent on Leaflet Thrombosis Detected by Cardiac MDCT after Transcatheter Aortic Valve Replacement. |
| Q35851558 | Impact of Dabigatran versus Phenprocoumon on ADP Induced Platelet Aggregation in Patients with Atrial Fibrillation with or without Concomitant Clopidogrel Therapy (the Dabi-ADP-1 and Dabi-ADP-2 Trials). |
| Q38378830 | Impact of Diabetes Mellitus on the Pharmacodynamic Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Acute Coronary Syndrome Patients Undergoing Ad Hoc Percutaneous Coronary Intervention |
| Q50059943 | Impact of Platelet Transfusion on Intracerebral Hemorrhage in Patients on Antiplatelet Therapy-An Analysis Based on Intracerebral Hemorrhage Score |
| Q38372841 | Impact of Timing on the Functional Recovery Achieved With Platelet Supplementation After Treatment With Ticagrelor |
| Q50662100 | Impact of an integrated treatment algorithm based on platelet function testing and clinical risk assessment: results of the TRIAGE Patients Undergoing Percutaneous Coronary Interventions To Improve Clinical Outcomes Through Optimal Platelet Inhibiti |
| Q38289218 | Impact of platelet phenotype on myocardial infarction. |
| Q43740353 | Impact of preoperative use of P2Y12 receptor inhibitors on clinical outcomes in cardiac and non-cardiac surgery: A systematic review and meta-analysis |
| Q40116423 | Impact of residual platelet reactivity on reperfusion in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention |
| Q38444425 | Impact of tailored anti-P2Y12 therapies in acute coronary syndromes |
| Q39949483 | Impact of the bioresorbable vascular scaffold surface area on on-treatment platelet reactivity |
| Q36226671 | Impaired platelet activation and cAMP homeostasis in MRP4-deficient mice. |
| Q50940254 | Implementation and evaluation of a CYP2C19 genotype-guided antiplatelet therapy algorithm in high-risk coronary artery disease patients. |
| Q40335176 | In Vivo and protease-activated receptor-1-mediated platelet activation in patients presenting for cardiac catheterization. |
| Q89294390 | In dubious battle: bleeding versus ischemic events |
| Q41343370 | Individualised dual antiplatelet therapy in a patient with short bowel syndrome after acute myocardial infarction with coronary artery stenting |
| Q34439089 | Individualising dual antiplatelet therapy after percutaneous coronary intervention: the IDEAL-PCI registry |
| Q35584168 | Influence of Morphine on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients with Acute Myocardial Infarction (IMPRESSION): study protocol for a randomized controlled trial |
| Q88194461 | Inhibitory mechanisms of very low-dose rivaroxaban in non-ST-elevation myocardial infarction |
| Q33437084 | Left main crossover stenting in a patient with severe thrombocytopenia due to aplastic anemia |
| Q39170298 | Lower Platelet Reactivity Is Associated with Presentation of Unstable Coronary Artery Disease |
| Q41982470 | Lower loading dose of prasugrel compared with conventional loading doses of clopidogrel and prasugrel in korean patients undergoing elective coronary angiography: a randomized controlled study evaluating pharmacodynamic efficacy |
| Q93379475 | Monitoring platelet function: what have we learned from randomized clinical trials? |
| Q36460862 | Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial |
| Q33898876 | Multi-parameter assessment of platelet inhibition and its stability during aspirin and clopidogrel therapy |
| Q38513891 | New oral anticoagulant and antiplatelet agents for neurosurgeons. |
| Q38916487 | Newly Formed Reticulated Platelets Undermine Pharmacokinetically Short-Lived Antiplatelet Therapies. |
| Q98222208 | Non-cardiac surgery in patients with coronary artery disease: risk evaluation and periprocedural management |
| Q59402673 | Non-traumatic splenic rupture on dual antiplatelet therapy with aspirin and ticagrelor after stenting for acute coronary syndrome. |
| Q38366950 | Novel anti-platelet agents in acute coronary syndrome: mechanisms of action and opportunities to tailor therapy. |
| Q38257119 | Novel antiplatelet agents in acute coronary syndrome |
| Q87155953 | Novel antiplatelet agents in cardiovascular medicine |
| Q57179203 | Novel aspects of antiplatelet therapy in cardiovascular disease |
| Q38780997 | Novel strategies for assessing platelet reactivity |
| Q38526074 | Optimal Duration of Dual Antiplatelet Therapy After DES Implantation: A Meta-Analysis of 11 Randomized Trials |
| Q90369202 | Optimal strategy of switching from clopidogrel to ticagrelor in Chinese acute coronary syndrome patients with complicated coronary artery disease: the switching from clopidogrel to ticagrelor (SHIFT-CACS) study |
| Q38754884 | Oral antiplatelet therapy: impact for transfusion medicine. |
| Q37522553 | Organ transplantation and drug eluting stents: Perioperative challenges |
| Q40257227 | Outcomes following implantation of the Biolimus A9-eluting BioMatrix coronary stent: Primary analysis of the e-BioMatrix registry |
| Q39221284 | P2Y12 receptor blockade synergizes strongly with nitric oxide and prostacyclin to inhibit platelet activation |
| Q53789736 | Parathyroid Hormone Levels and High-Residual Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy With Acetylsalicylic Acid and Clopidogrel or Ticagrelor. |
| Q38616610 | Peripheral interventions and antiplatelet therapy: Role in current practice |
| Q64949141 | Personalised antiplatelet therapy based on pharmacogenomics in acute ischaemic minor stroke and transient ischaemic attack: study protocol for a randomised controlled trial. |
| Q26775125 | Personalized antiplatelet therapy with P2Y12 receptor inhibitors: benefits and pitfalls |
| Q39382840 | Personalizing antiplatelet therapies: What have we learned from recent trials? |
| Q38189810 | Pharmacokinetic evaluation of prasugrel for the treatment of myocardial infarction. |
| Q38380461 | Pharmacology of antithrombotic drugs: an assessment of oral antiplatelet and anticoagulant treatments. |
| Q36984543 | Physician response to implementation of genotype-tailored antiplatelet therapy |
| Q41574497 | Platelet Aggregometry Testing: Molecular Mechanisms, Techniques and Clinical Implications. |
| Q92637510 | Platelet Function Test Use for Patients with Coronary Artery Disease in the Early 2020s |
| Q39341052 | Platelet Function Testing-Guided Antiplatelet Therapy |
| Q89980169 | Platelet Inhibition, Endothelial Function, and Clinical Outcome in Patients Presenting With ST-Segment-Elevation Myocardial Infarction Randomized to Ticagrelor Versus Prasugrel Maintenance Therapy: Long-Term Follow-Up of the REDUCE-MVI Trial |
| Q52912700 | Platelet Larger Cell Ratio and High-on Treatment Platelet Reactivity During Dual Antiplatelet Therapy. |
| Q52644169 | Platelet Signaling Pathways and New Inhibitors. |
| Q59355656 | Platelet Transcriptome Profiling in HIV and ATP-Binding Cassette Subfamily C Member 4 (ABCC4) as a Mediator of Platelet Activity |
| Q36216424 | Platelet aggregation and risk of stent thrombosis or bleeding in interventionally treated diabetic patients with acute coronary syndrome. |
| Q48761160 | Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial |
| Q38842001 | Platelet function testing as a biomarker for efficacy of antiplatelet drugs |
| Q38930441 | Platelet function testing in cardiac surgery |
| Q51746988 | Platelet function testing in contemporary clinical and interventional practice. |
| Q35121464 | Platelet function tests: a comparative review |
| Q26823775 | Platelet function tests: a review of progresses in clinical application |
| Q41517183 | Platelet reactivity in MitraClip patients |
| Q36244001 | Platelet reactivity in human immunodeficiency virus infected patients on dual antiplatelet therapy for an acute coronary syndrome: the EVERE2ST-HIV study |
| Q53240082 | Platelet reactivity in patients undergoing transcatheter aortic valve implantation. |
| Q48721104 | Platelet reactivity in patients with impaired renal function receiving dual antiplatelet therapy with clopidogrel or ticagrelor |
| Q51306353 | Platelet reactivity over time in coronary artery disease patients treated with a bioabsorbable everolimus-eluting scaffold. |
| Q92438951 | Platelet reactivity patterns in patients treated with dual antiplatelet therapy |
| Q50140654 | Platelet reactivity-adjusted antiplatelet therapy in patients with percutaneous coronary intervention: a meta-analysis of randomized controlled trials |
| Q38592772 | Platelet thrombin receptor antagonism with vorapaxar: pharmacology and clinical trial development |
| Q49609023 | Postoperative bleeding in coronary artery bypass patients on double antiplatelet therapy: predictive value of preoperative aggregometry |
| Q90246710 | Prasugrel effectively reduces the platelet reactivity units in patients with genetically metabolic dysfunction of cytochrome P450 2C19 who are treated with long-term dual antiplatelet therapy after undergoing drug-eluting stent implantation |
| Q38336838 | Prasugrel hydrochloride for the treatment of acute coronary syndromes. |
| Q39822915 | Predictive performance of adding platelet reactivity on top of CRUSADE score for 1-year bleeding risk in patients with acute coronary syndrome |
| Q53393756 | Predictors of high on-clopidogrel platelet reactivity in patients with acute coronary syndrome. |
| Q51625232 | Preoperative hemostatic testing and the risk of postoperative bleeding in coronary artery bypass surgery patients. |
| Q40958682 | Prevalence and predictors of high-on treatment platelet reactivity with ticagrelor in ACS patients undergoing stent implantation |
| Q47763354 | Prevalence and significance of CYP2C19*2 and CYP2C19*17 alleles in a New Zealand acute coronary syndrome population. |
| Q64097015 | Prevalence of clOpidogrel 'resIstaNce' in a selected population of patients undergoing elective percutaneous coronary intervention at a tertiary cardiovascular centre in Trinidad: the POINT pilot study |
| Q38616508 | Protease receptor antagonism to target blood platelet therapies |
| Q91788809 | Protease-activated receptor-mediated platelet aggregation in acute coronary syndrome patients on potent P2Y12 inhibitors |
| Q48628910 | Rationale and Design of the Effectiveness of LowEr maintenanCe dose of TicagRelor early After myocardial infarction (ELECTRA) pilot study |
| Q37039218 | Relationship between ADP-induced platelet-fibrin clot strength and anti-platelet responsiveness in ticagrelor treated ACS patients |
| Q37556037 | Relationship of Platelet Reactivity With Bleeding Outcomes During Long-Term Treatment With Dual Antiplatelet Therapy for Medically Managed Patients With Non-ST-Segment Elevation Acute Coronary Syndromes |
| Q57764181 | Residual platelet reactivity to predict long-term clinical outcomes after clopidogrel loading in patients with acute coronary syndromes: comparison of different cutoff values by light transmission aggregometry from the responsiveness to clopidogrel a |
| Q38258270 | Resistance to antiplatelet drugs: what progress has been made? |
| Q90250490 | Response to aspirin therapy in patients with myeloproliferative neoplasms depends on the platelet count |
| Q38532527 | Review of clopidogrel dose escalation in the current era of potent P2Y12 inhibitors |
| Q31155185 | Risk of bleeding and repeated bleeding events in prasugrel-treated patients: a review of data from the Japanese PRASFIT studies |
| Q49937577 | Risk of discontinuation of clopidogrel after 1 month following bare-metal stents: a propensity-score adjusted comparison with continued administration of clopidogrel after drug-eluting stents |
| Q38401281 | Role of Genetic Testing in Patients undergoing Percutaneous Coronary Intervention |
| Q90286198 | Safety of Percutaneous Dilatational Tracheotomy in Patients on Dual Antiplatelet Therapy and Anticoagulation |
| Q38716021 | Sepsis favors high-on-clopidogrel platelet reactivity |
| Q39187857 | Serial clopidogrel dose adjustment after platelet function testing improves outcome of acute coronary syndrome patients undergoing percutaneous coronary intervention with high on-treatment platelet reactivity |
| Q26746161 | State of the art: Oral antiplatelet therapy |
| Q30373414 | State-of-the-Art: Hypo-responsiveness to oral antiplatelet therapy in patients with type 2 diabetes mellitus. |
| Q38217692 | Strategies to reduce bleeding risk in acute coronary syndromes and percutaneous coronary intervention: new and emerging pharmacotherapeutic considerations. |
| Q92075011 | Stratified Approaches to Antiplatelet Therapies Based on Platelet Reactivity Testing |
| Q93092226 | Successful Use of Recombinant Activated Factor VII to Reverse Ticagrelor-Induced Bleeding Risk: A Case Report |
| Q49487264 | Successful coronary stenting in a patient with factor V deficiency in the absence of fresh frozen plasma transfusion: Case report. |
| Q38568711 | Switching P2Y12-receptor inhibitors in patients with coronary artery disease |
| Q35630654 | Switching from Clopidogrel to Prasugrel in patients undergoing PCI: A meta-analytic overview |
| Q52903362 | Switching from prasugrel to clopidogrel based on Cytochrome P450 2C19 genotyping in East Asian patients stabilized after acute myocardial infarction. |
| Q50055077 | T2238C Atrial Natriuretic Peptide Gene Variant and the Response to Antiplatelet Therapy in Stable Ischemic Heart Disease Patients. |
| Q91778278 | TRimetazidine as an Agent to affeCt clopidogrEl Response: The TRACER Study |
| Q42340635 | Tailored antiplatelet therapy in high-risk ACS patients treated with PCI stenting: lessons from the ANTARCTIC trial |
| Q51059922 | Tailored antiplatelet therapy to improve prognosis in patients exhibiting clopidogrel low-response prior to percutaneous coronary intervention for stable angina or non-ST elevation acute coronary syndrome. |
| Q92195567 | Temporal Variability of Platelet Reactivity in Patients Treated with Clopidogrel or Ticagrelor |
| Q40009280 | The Antiplatelet Effect of Clopidogrel Decreases With Patient Age. |
| Q54627886 | The CYP2C19*2 and CYP2C19*17 Polymorphisms play a Vital Role in Clopidogrel Responsiveness after Percutaneous Coronary Intervention: A Pharmacogenomics Study. |
| Q26801874 | The Emerging Role of miR-223 in Platelet Reactivity: Implications in Antiplatelet Therapy |
| Q41456276 | The PARTHENON Clinical Development Program: the Role of Ticagrelor in Patients with Atherothrombotic Disease |
| Q35925903 | The Ratio of ADP- to TRAP-Induced Platelet Aggregation Quantifies P2Y12-Dependent Platelet Inhibition Independently of the Platelet Count |
| Q91876173 | The Role of Clopidogrel in 2020: A Reappraisal |
| Q92276904 | The effect of the CYP2C19*2 allele on cardiovascular outcomes in patients with coronary artery stenting: a prospective study |
| Q38515684 | The future of P2Y12 receptor antagonists |
| Q100504013 | The need of a multicomponent guiding approach to personalize clopidogrel treatment |
| Q51063040 | The net clinical benefit of personalized antiplatelet therapy in patients undergoing percutaneous coronary intervention. |
| Q26801867 | The pharmacogenetic control of antiplatelet response: candidate genes and CYP2C19 |
| Q47865745 | The quest for safer antithrombotic treatment regimens in patients with coronary artery disease: new strategies and paradigm shifts |
| Q53450451 | Thrombelastographic hypercoagulability and antiplatelet therapy after coronary artery bypass surgery (TEG-CABG trial): a randomized controlled trial. |
| Q41968003 | Thrombin induced platelet-fibrin clot strength in relation to platelet volume indices and inflammatory markers in patients with coronary artery disease |
| Q64987954 | Thromboelastography-derived parameters for the prediction of acute thromboembolism following non-steroidal anti-inflammatory drug-induced gastrointestinal bleeding: A retrospective study. |
| Q89731964 | Ticagrelor Inhibits Toll-Like and Protease-Activated Receptor Mediated Platelet Activation in Acute Coronary Syndromes |
| Q38381383 | Ticagrelor pharmacokinetics and pharmacodynamics in patients with NSTEMI after a 180-mg loading dose |
| Q90647716 | Two common mutations within CYP2C19 affected platelet aggregation in Chinese patients undergoing PCI: a one-year follow-up study |
| Q59809182 | Uncontrolled Diabetes Mellitus Has No Major Influence on the Platelet Transcriptome |
| Q27016071 | Unmet needs in the management of acute myocardial infarction: role of novel protease-activated receptor-1 antagonist vorapaxar |
| Q38556885 | Update on antithrombotic therapy after percutaneous coronary revascularisation |
| Q50940673 | Validation of a New ELISA-Based Vasodilator-Associated Stimulated Phosphoprotein Phosphorylation Assay to Assess Platelet Reactivity Index in a Chinese Population. |
| Q51733137 | Validation of a P2Y12-receptor specific whole blood platelet aggregation assay. |
| Q60923889 | Variability of Platelet Reactivity on Antiplatelet Therapy in Neurointervention Procedure |
| Q48316634 | Variability of platelet response to clopidogrel is not related to adverse cardiovascular events in patients with stable coronary artery disease undergoing percutaneous coronary intervention. |
| Q38824971 | Vitamin D Binding Protein rs7041 polymorphism and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor |
| Q38829858 | Vitamin D levels and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor |
| Q92605722 | Vitamin D levels and platelet reactivity in diabetic patients receiving dual antiplatelet therapy |
| Q88361004 | [The role of point-of-care platelet function testing in guiding platelet transfusion] |
| Q51119287 | β-blockers are associated with decreased leucocyte-platelet aggregate formation and lower residual platelet reactivity to adenosine diphosphate after angioplasty and stenting. |
Search more.